Ensign Peak Advisors Inc Reduces Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Ensign Peak Advisors Inc decreased its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 95.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,091 shares of the biotechnology company’s stock after selling 64,453 shares during the period. Ensign Peak Advisors Inc’s holdings in Ascendis Pharma A/S were worth $422,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Private Ocean LLC acquired a new position in Ascendis Pharma A/S during the 1st quarter worth $36,000. GAMMA Investing LLC grew its holdings in Ascendis Pharma A/S by 52.0% during the 1st quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 102 shares in the last quarter. Bessemer Group Inc. grew its holdings in Ascendis Pharma A/S by 61.0% during the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 332 shares in the last quarter. Barometer Capital Management Inc. acquired a new position in Ascendis Pharma A/S during the 4th quarter worth $126,000. Finally, Searle & CO. acquired a new position in Ascendis Pharma A/S during the 2nd quarter worth $205,000.

Ascendis Pharma A/S Trading Down 1.9 %

ASND stock opened at $144.62 on Monday. Ascendis Pharma A/S has a 52 week low of $85.29 and a 52 week high of $161.00. The company has a market capitalization of $8.42 billion, a price-to-earnings ratio of -15.05 and a beta of 0.63. The firm’s 50-day moving average is $134.39 and its two-hundred day moving average is $136.36.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 154.18%. The company had revenue of $38.75 million for the quarter, compared to the consensus estimate of $94.74 million. On average, equities research analysts predict that Ascendis Pharma A/S will post -7.15 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have weighed in on ASND. Evercore ISI raised their price objective on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a report on Tuesday, September 17th. Jefferies Financial Group lifted their price target on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a report on Tuesday, August 13th. Bank of America lifted their price target on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a report on Monday, September 23rd. Wells Fargo & Company lifted their price target on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a report on Tuesday, September 17th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $190.00 price target (up from $180.00) on shares of Ascendis Pharma A/S in a report on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $195.00.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.